XB130 is overexpressed in prostate cancer and involved in cell growth and invasion
Metrics: PDF 1959 views | HTML 2767 views | ?
Bin Chen1,2,*, Mengying Liao3,*, Qiang Wei4,*, Feiye Liu5, Qinsong Zeng6, Wei Wang6, Jun Liu6, Jianing Hou7, Xinpei Yu8,9, Jian Liu9
1Department of Science and Training, General Hospital of Guangzhou Military Command of People’s Liberation Army, Guangzhou, Guangdong, China
2Guangzhou Huabo Biopharmaceutical Research Institute, Guangzhou, Guangdong, China
3Department Of Pathology, Peking University Shenzhen Hospital, Shenzhen, China
4Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
5Cancer Center, Traditional Chinese Medicine-Integrated Hospital of Southern Medical University, Guangzhou, Guangdong, China
6Department of Urology, General Hospital of Guangzhou Military Command of People’s Liberation Army, Guangzhou, Guangdong, China
7Sun Yat-Sen University, Guangzhou, China
8Guangdong Provincial Key Laboratory of Geriatric Infection and Organ Function Support and Guangzhou Key Laboratory of Geriatric Infection and Organ Function Support, Guangzhou, Guangdong, China
9Center for Geriatrics, General Hospital of Guangzhou Military Command of People’s Liberation Army, Guangzhou, Guangdong, China
*These authors contributed equally to this work
Xinpei Yu, email: [email protected]
Jian Liu, email: [email protected]
Keywords: XB130, adaptor protein, proliferation, invasion, Akt
Received: January 27, 2016 Accepted: June 29, 2016 Published: August 05, 2016
XB130 is a cytosolic adaptor protein involved in various physiological processes and oncogenesis of certain malignancies, but its role in the development of prostate cancer remains unclear. In current study, we examined XB130 expression in prostate cancer tissues and found that XB130 expression was remarkably increased in prostate cancer tissues and significantly correlated with increased prostate specific antigen (PSA), free PSA (f-PSA), prostatic acid phosphatase (PAP) and T classification. Patients with highly expressed XB130 had significantly decreased survival, which suggested XB130 as a possible prognostic indicator for prostate cancer. In vitro experiments showed that reduced XB130 expression restrained tumor growth both in vitro and in vivo. Furthermore, XB130 knockdown hindered transition of G1 to S phase in prostate cancer cell line DU145 and LNCap, which might contribute to the inhibition of cellular proliferation. Results from transwell assay demonstrated that downregulation of XB130 may attenuate invasion and metastasis of prostate cancer. Semiquantitative analysis of Western blot suggested that decreased XB130 expression was accompanied by diminished Akt signaling and EMT process. Thus, above observations suggest that XB130 may be a novel molecular marker and potent therapeutic target for prostate cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.